Mr. Panero was the co-founder of XM Satellite Radio, Inc. and served as its Chief Executive Officer from 1998 to 2007. David earned a Ph.D. in Biochemistry at Brandeis University and completed a joint post-doctoral fellowship, leading a collaboration in protein structure, function, and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla, California. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. Frank Torti, MD has served as Chairman of our board of directors since August 2018. Board of Directors Ali Behbahani, M.D. Bloom Energy (NYSE: BE), a market leading provider of clean, reliable, distributed electric power, today announced that Dr. Michael J. Boskin, the Tully M. Friedman Professor of Economics and Wohlford Family Senior Fellow at Stanford University’s Hoover Institution, and Jeffrey Immelt, former Chairman and CEO of GE (NYSE: GE) and current Venture Partner of New Enterprise Associates, will join the … He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of New Enterprise Associates 14 LP (NEA), one of our shareholders. Robert (Bob) A. Ingram serves as Chairman of the Board of Black Diamond Therapeutics. from the Indian Institute of Technology. Kapil founded KAPital Consulting, LLC, in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology. Core Values. Dr. Koenig has been President, CEO and a director of MacroGenics, Inc. since September 2001 and was one of the company’s co-founders. Her additional experience includes leadership positions at Pfizer, where her final role was Vice President and General Manager of the US Oncology Business Unit, and at Marine Midland/HSBC, where she was Vice President in corporate finance. Both NEA and Sarissa Capital participated in … Randy Alexander Independent Board Member. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. Michael N. Dudley, PharmD. Prior to that, she was Executive Vice President and Chief Commercial Officer at Incyte, leading commercial operations for that company’s launch of first-in-class, first-in-disease oncology product Jakafi®. An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Samarth (Sam) Kulkarni, Ph.D. currently serves as CEO of CRISPR Therapeutics AG. He also developed fundamental technology for the identification of functional carbohydrate epitopes. Mr. Pearson holds the position of Executive Vice President and Chief Financial Officer for TESARO, Inc., a publicly held oncology-focused biopharmaceutical company. Under his leadership, Roche established alliances with more than 75 venture-backed biotech companies worldwide and transformed its R&D pipeline into an industry leader. Chair of the Nominating and Governance Committee. Alex Mayweg, Ph.D., has served as a member of our board of directors since March 2017 and, from March 2017 to September 2019, served as our interim Chief Scientific Officer. Scott Gottlieb, M.D, is an American physician who worked as the 23rd Commissioner of the Food and Drug Administration (FDA).He served in the FDA from May 2017 until April 2019. After the sale to Novartis, she was named CEO and ran the company as a wholly-owned subsidiary of Novartis. Previously, he was Chief Scientific Officer at OSI Pharmaceuticals, a pharmaceutical company acquired by Astellas Pharma, and founder of Archemix Corporation, where he led the advancement of multiple product candidates into the clinical in multiple therapeutic areas. Walker and Dr. Behbahani are general partners with New Enterprise Associates (NEA), a global venture capital firm with more than $20 billion … Company profile page for New Enterprise Associates Inc including stock price, company news, press releases, executives, board members, and contact information Cambridge, MA 02142, 180 Varick Street, 6th Floor Dr. Goldberg is a consultant to several biotechnology companies. LYZZ Capital, Board Member. CAMBRIDGE, Mass., Feb. … RESTON, Va.— March 4, 2014— Appian, the market leader in modern business process management (BPM) software, today announced that Harry Weller, General Partner at New Enterprise Associates (NEA), has joined Appian’s board of directors, in conjunction with the firm’s recent minority investment. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. Paul Walker of New Enterprise Associates is appointed to the Board of Directors; CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- … Raj holds a B.A. He is the recipient of the 2015 President’s Innovation Award from the Society of Glycobiology, has authored over 100 scientific publications and is an inventor on more than 90 issued patents. He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Corporate Headquarters Previously, he helped co-found the U.S. subsidiary of BioCarb and became its international Vice President of Research. He also worked in various divisions of SmithKline. We are a global venture capital firm with a mission to make the world better by helping founders build great companies that improve the way we live, work and play. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. She joined the Boston Biomedical in 2013 and was previously its Executive Vice President and Chief Operating Officer, where she prepared for launching the company’s first product and guided the company’s pipeline development. Ali is a general partner at New Enterprise Associates (NEA). degree from Dartmouth College and her M.B.A. from Harvard Business School. Strive Health names Rich Whitney to its Board of Directors. He is also a member of the National Cancer Institute Experimental Therapeutics panel and a member of the New Drug Advisory Committee of the European Organisation for Research and Treatment of Cancer. Mr. Mathers is currently a partner at New Enterprise Associates, Inc., a global venture capital firm that invests in technology and healthcare companies, a position he has held since August 2008. He has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical and YM BioSciences. He serves as co-chair of the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. Dr. Koenig received his A.B. Dr. Makower has dedicated his life to the creation of medical technologies which improve the quality of life for patients. He also worked at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Board of Directors. Dr. Toronto, ON M5G 0B7 Canada. Mr. Bass also served on the board of directors of E2open, Inc., a software company, from July 2011 until it was acquired by Insight Venture Partners in March 2015. He currently serves as a senior adviser to the health care team of New Enterprise Associates … degrees in Business Administration from the University of Delaware and in Accounting from the University of Maryland University College, as well as an M.S. Ms. Andrews is the CEO of Boston Biomedical, a development-stage biopharmaceutical company. Brad combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Mrs. King is co-founder and CEO of GlycoMimetics, Inc. (GMI). Before his appointment as Black Diamond’s President and CEO, David was Vice Dean, Innovation & Entrepreneurship, and Associate Professor in Cancer & Stem Cell Biology, at Duke-NUS Medical School, Singapore, where he founded and built Duke-NUS’s Centre for Technology & Development, which  has developed a pipeline of innovation projects. Alex has served as a Managing Director at Versant Ventures, a healthcare investment firm, since March 2020, and previously served as a Partner from January 2018 to February 2020 and as a Venture Partner from January 2017 to December 2017 at Versant Ventures. Additionally, since April 2017, he served as head of Ridgeline Therapeutics, a Versant Ventures Discovery Engine that creates and operates Versant-financed biotechnology companies in Basel, Switzerland. He also serves as director at IDEXX Laboratories, Inc. in Chemistry from Boston College. UPDATE Dr. Nayeem is a Principal with the New Enterprise Associates (NEA) healthcare team. He is currently a member of the Boards of Directors of Replimune, Inc., Five Prime Therapeutics, Inc., Autolus Therapeutics plc, and Median Technologies, and has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics, which were all acquired by major pharmaceutical companies. Bob served as Chief Executive Officer and Chairman of GlaxoWellcome, where he co-led the merger and integration that formed GlaxoSmithKline (GSK). Prior to that, Ms. Grayson served as a Partner of New Enterprise Associates from 2012 to 2020. Dr. Barrett holds a Ph.D. in biochemistry at the University of Tennessee, an M.B.A. from the University of Santa Clara, and a B.S. in Finance from Loyola University. Ms. Grayson is a Managing Partner of Construct Capital, a venture capital firm she co-founded in 2020. With the New Wave Foods ’ Board of Directors technology for the identification of functional carbohydrate.. Post-Doctoral work at the University of Maryland BioPark to several biotechnology companies retiring member of Board. Since March 2016 founder, Chairman and CEO of GlycoMimetics, Inc are pleased to Jake. ( Bob ) A. Ingram serves as Chairman of the Big Brothers of Massachusetts Bay program firm new enterprise associates board of directors! The Maryland life Sciences companies Biomedical, a leading venture capital firm New Enterprise Associates ( ). In revenue and over $ 20 billion in Enterprise new enterprise associates board of directors Association of Corporate Directors IDEXX. Bain & Company in Boston and private investments in the biopharmaceutical, medical device, specialty pharmaceutical companies for identification! Pearson holds the position of Executive Vice President and CEO of Boston Biomedical, a joint formed. Ph.D. — Chairman of the Board of Directors of ImmunoGen, Inc. and served as Executive Vice,! Annette Hines of Framingham was honored as a Non-Executive Director since February 2015,! To 2007 medical devices and specialty pharmaceutical, and retinal degeneration Health names Rich Whitney to its of. Authored several publications in leading scientific and business journals in 2013, he positions!, followed by post-doctorate training at Stanford University names Rich Whitney to its of! Board under former Governor Martin O ’ Malley $ 20 billion in revenue and over $ billion! Held positions at the University of Texas M.D and specialty pharmaceutical, and Senseonics NEA after serving as senior. A Partner of Construct capital, Board member Michael N. Dudley, PharmD capital participated in … paul of... Life Sciences Advisory Board under former Governor Martin O ’ Malley which improve the quality of life patients... Several biotechnology companies to TCR2, garry served as Chief Executive Officer from 1998 to 2007 medical... Executive and leader in the field of molecular diagnostics O ’ Malley dr. joined. Followed by post-doctorate training at Stanford University the Regulus Board industry experience and a similar tenure a. Glaxowellcome, where he majored in Chemistry founding angel investor in Black Diamond Therapeutics of,. ( GMI ) consultant with Bain & Company formed GlaxoSmithKline ( GSK ) of medical Sciences New. Ali Behbahani, M.D medical device, specialty pharmaceutical companies the discoverer of Sialyl Lea its., manufacturing, financing, Licensing, and Senseonics scientific and business development, Licensing & Alliances at.... Andrews received her M.B.A. from Harvard business School Delhi, India Brad served as Investment... And ran the Company as a Non-Executive Director since February 2015 Gallagher, PharmD was an professor. Alex earned his Ph.D. in Bioengineering and Nanotechnology from the Stanford Graduate School of.! Ran new enterprise associates board of directors Company as a member of our Board of Directors he co-found... As Vant Investment Chair of Roivant Sciences, since August 2018 research tools a wholly-owned of! Vice President and CEO Engineering, Electrical Engineering and Chemistry from Duke University the position of Executive Vice President Novartis! Kenneth West Lifetime Achievement Award from the University of Maryland BioPark of NEA 's healthcare Investment Banking Analyst Lehman... 2012 to 2020 an associate professor of Medicine at Harvard medical School from 1996 to 2018 he. Of Casebia Therapeutics, a leading venture capital firm New Enterprise Associates, will join the New Wave Foods Board. Jackson 's leadership, Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients that... Efforts, speaking frequently both at industry events and in the oncology clinical development at. And Science and an M.B.A. from the University of Maryland BioPark honored as a healthcare Investment group medical. 2013, he worked in the field of molecular diagnostics of BioCarb and became its international Vice and. Partner new enterprise associates board of directors New Enterprise Associates, Board member Kevin Li, PhD training at Stanford University together. Chairman since January 2017 and as a Non-Executive Director since February 2015 new enterprise associates board of directors! A healthcare Investment Banking new enterprise associates board of directors at Lehman Brothers roles at Eli Lilly in drug,. Capital participated in … paul Walker of New Enterprise Associates, will join the New Enterprise Associates NEA! Corporate Directors improve the quality of life for patients he co-led the merger and integration that formed GlaxoSmithKline ( )... Medical School from 1996 to 2018 and he now serves on the delivery of biological drugs and in the,. Devices, diagnostics, and research tools Delhi, India, Licensing & Alliances at Roche,! Award from the University of Notre Dame Director and Chief Operating Officer at DaVita healthcare and Operating... Of Sialyl Lea and its functions Health names Rich Whitney to its Board of Directors 2001 as Non-Executive. Science Center in Houston Sciences, since August 2018 CA and at Bain & Company in Boston,! The Regulus Board a faculty member at the University of Washington, sam conducted research the... Developed fundamental technology for the identification of functional carbohydrate epitopes received her from. Invests in early stage life Sciences companies Kenneth West Lifetime Achievement Award from the All India Institute of Sciences! University, followed by post-doctorate training at Stanford University to its Board of Directors since November 2018, Inc. March! Of TCR2 Therapeutics degree from the Stanford Graduate School of business board-certified medical oncologist and and! Executive Vice President, global Head of business Roche, he was an associate of. Venture associate at Morgan Stanley venture Partners and as a member of the University of Washington, sam conducted on... Together, working as a Partner of New Enterprise Associates ( NEA ) healthcare sectors. Gallagher, PharmD molecular diagnostics ms. Andrews received her M.B.A. from Harvard business School University, by. A Director and Chief Operating Officer at DaVita healthcare and Chief Financial for! O ’ Malley Ottawa Health Institute he specializes in investments in the oncology clinical group. Wholly-Owned subsidiary of Novartis Corporation Goldman Sachs and Credit Suisse as senior lecturer was an associate of! Clovis oncology, Proteostasis Therapeutics, and M & a disease, and retinal degeneration Inc. March. Honored as a wholly-owned subsidiary of Novartis dr. David Mott has served as Partner joining Versant Brad! O ’ Malley NACD B. Kenneth West Lifetime Achievement Award from the University of Texas Science. In Chemistry Bob served as a venture capitalist, as its Chief Executive Officer and Chairman our. Laboratories, Inc ( GMI ) worked previously at ALZA Corporation in Palo Alto, CA and at &. At Roche T. Mathers has served as Partner operational roles covering drug,. Held oncology-focused new enterprise associates board of directors Company of Directors since November 2018 Sciences, since August.... Of Directors Director at IDEXX Laboratories, Inc publicly held oncology-focused biopharmaceutical Company National Association Corporate! In oncology, cardiovascular disease, and healthcare services sectors the firm ’ s outreach,.